Skip to main content

Table 1 Baseline subject demographics

From: Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study

Variable   Group
Active Placebo
N   6 6
Age Mean (SD) 41 (15) 52 (15)
Sex #(%) Male 4 (67%) 3 (50%)
Duration UC Mean (SD) yrs 8.9 (9.1) 9.8 (10.6)
BMI* Mean (SD) 24 (3) 29 (4)
Treatment with biologic #(%) yes 2 (33%) 1 (17%)
Fecal calprotectin Mean (SD) 573 (659) 408 (277)
Total Mayo score Mean (SD) 6.3 (2.0) 6.7 (1.2)
 Mayo symptom subscore Mean (SD) 4.8 (1.5) 4.3 (1.0)
 Mayo endoscopic subscore Mean (SD) 1.5 (0.8) 2.3 (0.5)
Endoscopic UCEIS^ score Mean (SD) 7.0 (1.8) 8.5 (1.8)
Histologic Severity Score** Mean (SD) 3.4 (1.2) 4.3 (2.0)
IBDQ^^ total score Mean (SD) 142.8 (16.8) 120.2 (25.1)
 IBDQ bowel system subscore Mean (SD) 4.2 (0.7) 4.3 (0.9)
  1. Baseline clinical characteristics of subjects randomized to both the active FMT and placebo study arms
  2. *Body Mass Index
  3. **Geboes Score
  4. ^Ulcerative Colitis Endoscopic Index of Severity
  5. ^^Inflammatory Bowel Questionnaire